Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy set to lose 180-day exclusivity on three products, potentially five more as it begins process to meet new requirements.
You may also be interested in...
Ranbaxy Woes Continue With 30-plus Product Import Alert
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.